Treatment for Acute Gout Attack with Hyperuricemia

Immediate Management of the Acute Attack

The American College of Rheumatology recommends initiating treatment within 24 hours using NSAIDs, corticosteroids, or low-dose colchicine as first-line options, and do not stop any established urate-lowering therapy during the acute attack 1
The American College of Rheumatology suggests that low-dose colchicine is equally effective as high-dose colchicine for acute attacks but causes significantly fewer gastrointestinal adverse events 1
The American College of Rheumatology states that corticosteroids (oral, intravenous, or intra-articular) are appropriate alternatives, particularly in patients with contraindications to NSAIDs or colchicine 1, 2
The American College of Rheumatology recommends that cyclooxygenase-2 inhibitors are associated with fewer total adverse events and fewer withdrawals due to adverse events compared to traditional NSAIDs 2

The American College of Rheumatology recommends that the goal of urate-lowering therapy is to reduce serum uric acid below 6 mg/dL to prevent future attacks and tophi formation 1, 3
The American College of Rheumatology suggests that allopurinol is the first-line urate-lowering therapy, starting at 100 mg daily, with gradual upward titration every 2-5 weeks to achieve target serum uric acid <6 mg/dL 4, 3, 1
The American College of Rheumatology recommends that the dose can be raised above 300 mg daily, even with renal impairment, provided there is adequate patient education and monitoring for toxicity 4, 3
The American College of Rheumatology states that febuxostat can be substituted for allopurinol in cases of drug intolerance, adverse events, or failure of upward dose titration 4, 3

The American College of Rheumatology recommends that all patients starting urate-lowering therapy require prophylactic anti-inflammatory medication to prevent acute flares during the initial treatment period 1
The American College of Rheumatology suggests that colchicine (low-dose) or low-dose NSAIDs are appropriate first-line prophylaxis options 1

The American College of Rheumatology recommends monitoring serum uric acid levels every 2-5 weeks during dose titration to ensure levels remain below 6 mg/dL 4, 3